Adult Dosing
Steroid-responsive dermatoses
- Apply once or twice daily
- Max:
- CRE: 45 g/wk
- OINT,GEL: 50 g/wk
- LOTN: 50 mL/wk
Notes:- Reassess diagnosis if no improvement is seen within 2 wks of therapy
- Avoid using with occlusive dressings
Pediatric Dosing
Steroid-responsive dermatoses
- >12 yrs: Apply once or twice daily
- Max:
- CRE: 45 g/wk
- OINT,GEL: 50 g/wk
- LOTN: 50 mL/wk
Notes:- Reassess diagnosis if no improvement is seen within 2 wks of therapy
- Avoid using with occlusive dressings
See Supplemental Patient Information
- Systemic absorption of topical corticosteroids is associated with reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria
- Use of more than one corticosteroid-containing product at the same time is associated with increased total systemic glucocorticoid exposure
- Avoid treating patients with amounts of lotion/ointment/gel >50 mL/wk or >50 g/wk and cream >45 g/wk because of the potential for the drug to suppress HPA axis. Avoid treating patients receiving super-potent corticosteroids >2 wks at a time and treat only small at any one time due to the increased risk of HPA axis suppression
- Avoid using lotion/ointment/gel/cream in the treatment of rosacea or perioral dermatitis and on the face, groin or in the axillae
- Application of dose 14 mg/day is associated with reducing the plasma levels of adrenal cortical hormones following repeated application to diseased skin in patients with psoriasis. Application of 7 mg/day dose causes minimal inhibition of the HPA axis
- Periodically evaluate patients receiving a higher dose of a potent topical steroid to a large surface for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. On presence of HPA axis suppression make an attempt to discontinue the drug, to reduce the frequency of application, or to substitute with a less potent steroid. Recovery from HPA axis function is generally prompt and complete upon withdrawal of this drug
- Signs and symptoms of steroid withdrawal have occurred; provide supplemental systemic corticosteroids for treating such symptoms
- Children are more susceptible to systemic toxicity
- On occurrence of irritation discontinue topical corticosteroids and institute appropriate therapy
- Use appropriate antifungal or antibacterial agent in the presence of dermatological infections
- On failure of occurrence of prompt favorable response discontinue corticosteroid until the infections are adequately controlled
Caution: Use cautiously in
- Pediatrics
- Skin infections
Supplemental Patient Information
- Advise patients to use this medication as directed by the physician and to strictly adhere to dosage instructions
- Advise patients to consult their physician on any signs of local adverse reactions
Pregnancy Category:C
Breastfeeding: Topical betamethasone has not been evaluated during breastfeeding. Unlikely that short-term application of would pose a risk to the breastfed infant. Use the least potent drug on the smallest area of skin possible. Ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated. Use lower potency corticosteroids on the nipple or areola where the infant could directly ingest the drugs from the skin. Apply only water-miscible cream or gel products to the breast because ointments may expose the infant to high levels of mineral paraffins via licking. Wiped off any topical corticosteroid prior to nursing if it is applied to the breast or nipple area. This data is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 18 February 2011). Manufacturer advises caution.
US Trade Name(s)
US Availability
betamethasone dipropionate (generic)
- CRE: 0.05%
- OINT: 0.05%
- LOTN: 0.05%
- AUGMENTED GEL: 0.05%
- AUGMENTED OINT: 0.05%
- AUGMENTED CRE: 0.05%
- AUGMENTED LOTN: 0.05%
Diprolene
- AUGMENTED OINT: 0.05%
- AUGMENTED LOTN: 0.05%
Diprolene AF
Canadian Trade Name(s)
- Diprolene
- Topilene
- Diprosone
- Topisone
- Rolene
- Rosone
- Sone
Canadian Availability
Diprolene, Topilene
- CRE: 0.5 mg/g
- LOTN: 0.5 mg/g
- OINT: 0.5 mg/g
Diprosone, Topisone, Rolene, Rosone
- CRE: 0.05%
- LOTN: 0.05%
- OINT: 0.05%
Sone
UK Trade Name(s)
UK Availability
Diprosone
- CRE: 0.05%
- LOTN: 0.05%
- OINT: 0.05%
Australian Trade Name(s)
- Diprosone
- Eleuphrat
- Diprosone OV
Australian Availability
Diprosone, Eleuphrat
- CRE: 0.5 mg/g
- LOTN: 0.5 mg/g
- OINT: 0.5 mg/g
Diprosone OV
- CRE: 0.5 mg/g
- OINT: 0.5 mg/g
Pricing data from www.DrugStore.com in U.S.A.
- Betamethasone Dipropionate 0.05 % LOTN [Bottle] (PERRIGO PHARMACEUTICALS)
60 % = $48.99
180 % = $129.96 - Betamethasone Dipropionate Aug 0.05 % GEL [Tube] (TARO)
50 % = $79.99
150 % = $215.98 - Diprolene 0.05 % LOTN [Bottle] (SCHERING)
30 % = $83.44
90 % = $239.09 - Betamethasone Dipropionate Aug 0.05 % GEL [Tube] (TARO)
15 % = $39.99
45 % = $105.97 - Diprolene 0.05 % LOTN [Bottle] (SCHERING)
60 % = $156.93
180 % = $452.09 - Diprolene AF 0.05 % CREA [Tube] (SCHERING)
50 % = $155.7
150 % = $448.4 - Diprolene 0.05 % OINT [Tube] (SCHERING)
15 % = $69.89
45 % = $201.2 - Betamethasone Dipropionate 0.05 % CREA [Tube] (ACTAVIS MID ATLANTIC)
45 % = $65.99
90 % = $120.97 - Betamethasone Dipropionate 0.05 % OINT [Tube] (ACTAVIS MID ATLANTIC)
45 % = $81.99
135 % = $221.96 - Diprolene 0.05 % OINT [Tube] (SCHERING)
50 % = $156.11
150 % = $448.84 - Betamethasone Dipropionate 0.05 % CREA [Tube] (ACTAVIS MID ATLANTIC)
15 % = $38.99
45 % = $105.97 - Betamethasone Dipropionate 0.05 % OINT [Tube] (ACTAVIS MID ATLANTIC)
15 % = $49.99
45 % = $125.98 - Diprolene AF 0.05 % CREA [Tube] (SCHERING)
15 % = $73.48
45 % = $208.01
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
13 yrs of age